Trial Profile
Multicenter Phase I/Ib Trial of Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Sep 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Vorinostat (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- 30 Mar 2021 Planned End Date changed from 1 Sep 2022 to 1 Sep 2024.
- 30 Mar 2021 Planned primary completion date changed from 1 Mar 2022 to 1 Mar 2024.
- 30 Mar 2021 Status changed from not yet recruiting to recruiting.